Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 53 of 6351
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control CancelledThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evalu…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New triple therapy could extend lives in stomach cancer
Disease control Not yet recruitingGastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). …
Phase 3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
BiTE antibodies could unlock transplants for 'Incompatible' kidney patients
Disease control Not yet recruitingThis study is a prospective, open-label, two-arm exploratory clinical trial aimed at evaluating the safety and efficacy of Bispecific T-cell Engager (BiTE) therapies in refractory, highly sensitized kidney transplant candidates. Patients with end-stage renal disease (ESRD) who ha…
Phase 4 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control Not yet recruitingThis is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE NDMM, compared with the SoC PERSEUS regimen. A tot…
Phase 3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Short-Course radiation may boost immunotherapy and chemo for stomach cancer
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and mee…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental brain cancer therapy targets tumors directly
Disease control Not yet recruitingThis is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) …
Phase 2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowPhase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembroliz…
Phase 1/2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could MDMA help veterans heal from PTSD? new study investigates
Symptom relief Recruiting nowA Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Smartphone app aims to prevent strokes by catching silent atrial fibrillation
Prevention Recruiting nowThe Austrian Digital Heart Study is a population-based, siteless, randomized, controlled digital trial testing whether a smartphone-based atrial fibrillation screening and management pathway reduces stroke hospitalizations compared with usual care. Adults aged 65 years or older i…
Sponsor: Medical University Innsbruck • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Recruiting nowThe purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Phase 3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Teens create videos to stop gun violence before it starts
Prevention By invitation onlyGun violence is the number one reason children die in the U.S. In big cities, most of these cases come from shootings related to assaults and homicides. There aren't many effective ways right now to prevent kids from either becoming victims or getting involved in gun violence the…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid in Graves' disease
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Phase 3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Gene test may spare young breast cancer patients from chemo
Disease control Recruiting nowRationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug associated with ovarian suppression (OFS), improve surv…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
Disease control Not yet recruitingThis study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastri…
Phase 3 • Sponsor: Peking University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control By invitation onlyThis study is a pilot, open-lable, two-arm study. The investigators will enroll virally suppressed people living with HIV and obesity to evaluate the effect of tirzepatide on epigenetic aging, assessed by DNA methylation-based clocks using peripheral blood. In parallel, imaging s…
Phase 4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
Disease control Recruiting nowhis multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body radiotherapy (SBRT) as neoadjuvant therapy in patien…
Phase 4 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
Disease control Recruiting nowTo compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Phase 3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThe preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability, tumor targeting capability, and infection efficiency…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy offers new hope for kids with brittle bone disease
Disease control Recruiting nowThis is a non-randomized, one-arm, open label, single-center, phase I/II, prospective study, to assess safety, feasibility and efficacy of FT024 in 8 children (Age: ≥ 28 days and ≤ 2 years old, Body weight: ≥ 4 kg) affected by ARO-1. Once written informed consent has been obtain…
Phase 1/2 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for KRAS lung cancer: targeted pill plus immunotherapy in Late-Stage trial
Disease control Recruiting nowResearchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after ch…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC